AstraZeneca Results Presentation Deck

Rare Disease Q3 2021 Total Revenue $1.3bn 31 $m 900 800 700 600 500 400 300 200 100 0 Rare disease Pro-forma global growth, Q3 2021 +7% li.. +12% +9% US Pro-forma Q3 2020¹ Q3 2021 EU EROW IMDC = Independent Data Monitoring Committee; AL = amyloid light-chain. 1. geographic splits restated. -31% EM Multiple Phase III results across both LCM and NMES • Positive Phase III results for Ultomiris in generalised myasthenia gravis Phase III trial for Ultomiris in amyotrophic lateral sclerosis stopped for futility on IDMC recommendation • Positive Phase III results for ALXN1840 in Wilson disease • Acquired Caelum Biosciences: CAEL-101 Phase III ● development in AL amyloidosis to be accelerated B

View entire presentation